Sage Advises PolyPid on Exclusive U.S. and Canadian Commercial Partnership with Azurity Pharmaceuticals for D-PLEX100
- 18 hours ago
- 3 min read
Sage acted as transaction adviser to PolyPid on the North American commercialisation agreement
LONDON, 3 September 2026
Sage is a specialist global life-sciences transaction advisory firm, is pleased to confirm that it acted as transaction adviser to PolyPid Ltd. (Nasdaq: PYPD) in connection with its exclusive commercial partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the United States and Canada for the prevention of abdominal colorectal surgical site infections.
Under the publicly disclosed terms of the agreement, PolyPid is eligible to receive up to approximately $320 million in total upfront and milestone payments. Following the FDA's acceptance of the D-PLEX100 New Drug Application with Priority Review, PolyPid announced that it had achieved the milestones required for $30 million in upfront and near-term payments. The agreement also provides for tiered royalties ranging from mid-teen to mid-twenties percentages on U.S. and Canadian sales, together with product supply economics.
Azurity will commercialize D-PLEX100 in the United States and Canada, subject to regulatory approval, while PolyPid will manufacture and supply the product. The parties may also agree to jointly pursue potential label expansions into additional surgical site infection indications beyond abdominal colorectal surgeries, with Azurity providing funding for agreed clinical development programs. PolyPid retains commercial rights outside the United States and Canada, worldwide manufacturing rights, and full ownership of its Kynatrix™ technology and pipeline.
The transaction follows positive results from PolyPid's Phase 3 SHIELD II trial, in which D-PLEX100 met its primary endpoint and all key secondary endpoints, including a 60% relative risk reduction in surgical site infections compared with standard of care (p=0.0013). The FDA has assigned a PDUFA goal date of 28 November 2026.
"We are pleased to have advised PolyPid on this important partnership, which brings together PolyPid's development and manufacturing capabilities with Azurity's focused North American hospital commercial platform. We congratulate both teams on completing the transaction," said Wayne Pambianchi, Executive Director of Sage.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow them on Twitter (X) and LinkedIn.
.
About Sage
Sage is a specialist global transaction advisory firm focused exclusively on life sciences. Sage advises pharmaceutical, biotechnology, medical technology, diagnostics and advanced-therapy companies on licensing, partnering, M&A and strategic transactions. Over more than 30 years, Sage's principals have worked with more than 300 multinational clients and transactions worldwide, representing billions of dollars in aggregate value. Sage combines senior deal leadership, direct access to corporate decision-makers and proprietary AI-enabled intelligence through SAGEIQ™. For additional information, visit www.sagehealthcare.com.
Media Contact
Dr Bill Mason, Executive Director
Sage Healthcare Ltd
+44 (0)7785 950134
PolyPid Investor Relations and Media Contacts Ori Warshavsky908-858-5995 IR@Polypid.com
Arx Investor Relations North American Equities Desk polypid@arxhq.com
Azurity Pharmaceuticals Media
Contacts Media Relations media@azurity.com
Comments